Recruiting

Adjustable Continence Therapy

Sponsor:

Uromedica

Code:

NCT04248283

Conditions

Urinary Incontinence

Urinary Incontinence,Stress

Eligibility Criteria

Sex: Female

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Adjustable Continence Therapy for Women (ACT)

Study Details

Brief summary:

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Conditions

Urinary Incontinence

Urinary Incontinence,Stress

Study ID

NCT04248283

Start date

Jan 26, 2021

Status verified date

Jun, 2026

Completion date

May 31, 2032

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Female at least 22 years old
2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
3. Provocative pad weight of greater than 11.0 grams
4. Candidate for surgical intervention
5. Negative urinalysis
6. Normal cystourethroscopy
7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
8. Willing and able to sign informed consent and comply with trial follow-up requirements

Exclusion Criteria:

1. Pregnant or lactating
2. Life expectancy of less than 5 years
3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
4. Has auto-immune disease
5. Undergoing radiation therapy
6. Active urinary tract infection
7. Detrusor instability refractory to medication
8. Reduced bladder compliance as defined by a cystometrogram
9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
10. Has, had, or is suspected of having bladder cancer
11. History of bladder stones
12. Urethral stricture evidenced during cystourethroscopy
13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
14. Has a diathesis, hemophilia, or a bleeding disorder
15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
16. Had prior pelvic radiotherapy
17. Had a prior artificial urinary sphincter implanted
18. Has a neurogenic condition known to affect bladder/sphincter function

Study Design

Enrollment

167 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Adjustable Continence Therapy for Women

Implantation of the Adjustable Continence Therapy for the treatment of female SUI.

Interventions

Adjustable Continence Therapy for Women (ACT)

Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).

Primary outcome measure

  • Provocative pad weight [ Time Frame: 12 months ]

Central Contacts and Locations

Locations

University of Colorado

Recruiting

Denver, Colorado, United States, 80045

Contacts

Principal Investigator:

Brian Flynn, MD

CHI Health Research Center

Recruiting

Omaha, Nebraska, United States, 68124

Contacts

Principal Investigator:

Michael Feloney, MD

More Information

Sponsor

Uromedica

Last update posted

Jun 17, 2026

Last verified

Jun, 2026

Keywords

  • Urinary Incontinence
  • Urination Disorders
  • Urination Involuntary
  • Urologic Diseases
  • Lower Urinary Tract Symptoms

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Uromedica on 2026-06-17.